Succinate dehydrogenase mutations in head and neck paragangliomas: A systematic review and meta-analysis of individual patients' data.
carotid body tumor
head and neck
head and neck paraganglioma
meta-analysis
succinate dehydrogenase
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
25 Jan 2024
25 Jan 2024
Historique:
revised:
03
01
2024
received:
25
09
2023
accepted:
12
01
2024
medline:
26
1
2024
pubmed:
26
1
2024
entrez:
26
1
2024
Statut:
aheadofprint
Résumé
Head and neck paragangliomas (HNPs) have been associated with gene mutations in the succinate dehydrogenase (SDH) complex, but the clinical significance remains unclear. We sought to explore the demographics, clinical characteristics, treatment methods, and outcomes of SDH-mutated HNPs. Databases were systematically searched. Pooled event ratio and relative 95% confidence intervals were calculated for dichotomous outcomes. Meta-regression was performed. Cochran's Q test and I Forty-two studies with 8849 patients were included. Meta-regression revealed a significant correlation between multifocality and SDHD mutations (0.03 ± 0.006, p < 0.0001) and between distant metastases and SDHB mutations (0.06 ± 0.023, p = 0.008). There was no correlation between sex, age, tumor size, or familial occurrences and SDH-related mutations. Multifocality of HNPs correlates with the SDHD mutational subtype, and metastases correlate with the SDHB subtype. Knowledge of HNP phenotypes associated with SDH-related mutations has the potential to influence the management approach to such HNPs.
Sections du résumé
BACKGROUND
BACKGROUND
Head and neck paragangliomas (HNPs) have been associated with gene mutations in the succinate dehydrogenase (SDH) complex, but the clinical significance remains unclear. We sought to explore the demographics, clinical characteristics, treatment methods, and outcomes of SDH-mutated HNPs.
METHODS
METHODS
Databases were systematically searched. Pooled event ratio and relative 95% confidence intervals were calculated for dichotomous outcomes. Meta-regression was performed. Cochran's Q test and I
RESULTS
RESULTS
Forty-two studies with 8849 patients were included. Meta-regression revealed a significant correlation between multifocality and SDHD mutations (0.03 ± 0.006, p < 0.0001) and between distant metastases and SDHB mutations (0.06 ± 0.023, p = 0.008). There was no correlation between sex, age, tumor size, or familial occurrences and SDH-related mutations.
CONCLUSION
CONCLUSIONS
Multifocality of HNPs correlates with the SDHD mutational subtype, and metastases correlate with the SDHB subtype. Knowledge of HNP phenotypes associated with SDH-related mutations has the potential to influence the management approach to such HNPs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Baysal BE. Hereditary paraganglioma targets diverse paraganglia. J Med Genet. 2002;39(9):617-622. doi:10.1136/jmg.39.9.617
Cass ND, Schopper MA, Lubin JA, Fishbein L, Gubbels SP. The changing paradigm of head and neck paragangliomas: what every otolaryngologist needs to know. Ann Otol Rhinol Laryngol. 2020;129(11):1135-1143. doi:10.1177/0003489420931540
Taïeb D, Kaliski A, Boedeker CC, et al. Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev. 2014;35(5):795-819. doi:10.1210/er.2014-1026
Valero C, Ganly I, Shah JP. Head and neck paragangliomas: a 30-year experience. Head Neck. 2020;42(9):2486-2495. doi:10.1002/hed.26277
Mediouni A, Ammari S, Wassef M, et al. Malignant head/neck paragangliomas. Comparative study. Eur Ann Otorhinolaryngol Head Neck Dis. 2014;131(3):159-166. doi:10.1016/j.anorl.2013.05.003
Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol. 2022;33(1):90-114. doi:10.1007/s12022-022-09704-6
Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(7):839-868. doi:10.6004/jnccn.2021.0032
Galan SR, Kann PH. Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma. Clin Endocrinol (Oxf). 2013;78(2):165-175. doi:10.1111/cen.12071
Fishbein L, Nathanson KL. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet. 2012;205(1-2):1-11. doi:10.1016/j.cancergen.2012.01.009
Hensen EF, Bayley JP. Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Fam Cancer. 2011;10(2):355-363. doi:10.1007/s10689-010-9402-1
Turchini J, Cheung VKY, Tischler AS, De Krijger RR, Gill AJ. Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology. 2018;72(1):97-105. doi:10.1111/his.13402
Dalla Pozza E, Dando I, Pacchiana R, et al. Regulation of succinate dehydrogenase and role of succinate in cancer. Semin Cell Dev Biol. 2020;98:4-14. doi:10.1016/j.semcdb.2019.04.013
Hoekstra AS, Bayley JP. The role of complex II in disease. Biochim Biophys Acta. 2013;1827(5):543-551. doi:10.1016/j.bbabio.2012.11.005
Gill AJ. Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology. 2018;72(1):106-116. doi:10.1111/his.13277
Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer. Biochim Biophys Acta. 2011;1807(11):1432-1443. doi:10.1016/j.bbabio.2011.07.003
Tufton N, Sahdev A, Akker SA. Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers. J Endocr Soc. 2017;1(7):897-907. doi:10.1210/js.2017-00230
Rijken JA, de Vos B, van Hest LP, et al. Evolving management strategies in head and neck paragangliomas: a single-centre experience with 147 patients over a 60-year period. Clin Otolaryngol. 2019;44(5):836-841. doi:10.1111/coa.13380
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg Lond Engl. 2021;88:105906. doi:10.1016/j.ijsu.2021.105906
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. doi:10.1136/bmj.j4008
Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-randomized Studies in Meta-analysis. Ottawa Hospital Research Institute; 2000.
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928
Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41. doi:10.1186/1471-2288-11-41
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation; 2021. https://www.R-project.org/
Neumann HPH, Erlic Z, Boedeker CC, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009;69(8):3650-3656. doi:10.1158/0008-5472.CAN-08-4057
Jafri M, Whitworth J, Rattenberry E, et al. Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol (Oxf). 2013;78(6):898-906. doi:10.1111/cen.12074
Williams ST, Chatzikyriakou P, Carroll PV, et al. SDHC phaeochromocytoma and paraganglioma: a UK-wide case series. Clin Endocrinol (Oxf). 2022;96(4):499-512. doi:10.1111/cen.14594
Ellis RJ, Patel D, Prodanov T, Nilubol N, Pacak K, Kebebew E. The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas. Ann Surg. 2014;260(1):158-162. doi:10.1097/SLA.0000000000000283
Richter S, Qiu B, Ghering M, et al. Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocr Relat Cancer. 2022;29(4):213-224. doi:10.1530/ERC-21-0359
Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39(3):178-183. doi:10.1136/jmg.39.3.178
Rijken JA, Niemeijer ND, Leemans CR, et al. Nationwide study of patients with head and neck paragangliomas carrying SDHB germline mutations. BJS Open. 2018;2(2):62-69. doi:10.1002/bjs5.39
Reichert T, Fakhry N, Lavieille JP, et al. Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: a 18 F-FDOPA PET/CT study in head and neck paragangliomas. Clin Endocrinol (Oxf). 2019;91(6):879-884. doi:10.1111/cen.14086
Ding Y, Feng Y, Wells M, Huang Z, Chen X. SDHx gene detection and clinical phenotypic analysis of multiple paraganglioma in the head and neck. Laryngoscope. 2019;129(2):E67-E71. doi:10.1002/lary.27509
Fakhry N, Niccoli-Sire P, Barlier-Seti A, Giorgi R, Giovanni A, Zanaret M. Cervical paragangliomas: is SDH genetic analysis systematically required? Eur Arch Otorhinolaryngol. 2008;265(5):557-563. doi:10.1007/s00405-007-0517-4
Persu A, Hamoir M, Grégoire V, et al. High prevalence of SDHB mutations in head and neck paraganglioma in Belgium. J Hypertens. 2008;26(7):1395-1401. doi:10.1097/HJH.0b013e3282ffdc54
Domingues R, Montalvão P, Magalhães M, Santos R, Duarte L, Bugalho MJ. Identification of three new variants of SDHx genes in a cohort of Portuguese patients with extra-adrenal paragangliomas. J Endocrinol Invest. 2012;35(11):975-980. doi:10.3275/8237
Michałowska I, Ćwikła JB, Michalski W, et al. Growth rate of paragangliomas related to germline mutations of the SDHX genes. Endocr Pract. 2017;23(3):342-352. doi:10.4158/EP161377.OR
Snezhkina A, Fedorova M, Kobelyatskaya A, et al. The SDHD:p.H102R variant is frequent in Russian patients with head and neck paragangliomas and associated with loss of 11p15.5 region and hypermethylation of H19-DMR. Int J Mol Sci. 2022;24(1):628. doi:10.3390/ijms24010628
Gul AE, Keser SH, Barisik NO, Gurbuz YS, Sensu S, Erdogan N. Succinate dehydrogenase complex iron sulfur subunit B (SDHB) immunohistochemistry in pheochromocytoma, head and neck paraganglioma, thoraco-abdomino-pelvic paragangliomas: Is it a good idea to use in routine work? Asian Pac J Cancer Prev. 2021;22(6):1721-1729. doi:10.31557/APJCP.2021.22.6.1721
Lima J, Feijão T, Ferreira da Silva A, et al. High frequency of germline succinate dehydrogenase mutations in sporadic cervical paragangliomas in northern Spain: mitochondrial succinate dehydrogenase structure-function relationships and clinical-pathological correlations. J Clin Endocrinol Metab. 2007;92(12):4853-4864. doi:10.1210/jc.2007-0640
Enríquez-Vega ME, Muñoz-Paredes JG, Cossío-Zazueta A, Ontiveros-Carlos Y, Pacheco-Pittaluga E, Bizueto-Rosas H. SDHD gene mutation in Mexican population with carotid body tumor. Cir Cir. 2019;86(1):33-37. doi:10.24875/cirue.m18000005
González-Orús Álvarez-Morujo RJ, Arístegui Ruiz MÁ, da Costa BJ, Martinez Guirado T, Scola YB. Head and neck paragangliomas: experience in 126 patients with 162 tumours. Acta Otorrinolaringol Esp. 2015;66(6):332-341. doi:10.1016/j.otorri.2014.11.002
Hermsen MA, Sevilla MA, Llorente JL, et al. Relevance of germline mutation screening in both familial and sporadic head and neck paraganglioma for early diagnosis and clinical management. Cell Oncol. 2010;32(4):275-283. doi:10.3233/CLO-2009-0498
Sevilla MA, Hermsen MA, Weiss MM, et al. Chromosomal changes in sporadic and familial head and neck paragangliomas. Otolaryngol Head Neck Surg. 2009;140(5):724-729. doi:10.1016/j.otohns.2009.01.004
Donato S, Simões H, Pinto AT, Cavaco BM, Leite V. SDHx-related pheochromocytoma/paraganglioma-genetic, clinical, and treatment outcomes in a series of 30 patients from a single center. Endocrine. 2019;65(2):408-415. doi:10.1007/s12020-019-01953-6
Yoshihama K, Mutai H, Sekimizu M, et al. Molecular basis of carotid body tumor and associated clinical features in Japan identified by genomic, immunohistochemical, and clinical analyses. Clin Genet. 2023;103(4):466-471. doi:10.1111/cge.14294
Amodru V, Romanet P, Scemama U, et al. Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: a 18F-FDOPA PET/CT study. Head Neck. 2019;41(6):1565-1571. doi:10.1002/hed.25604
Davila VJ, Chang JM, Stone WM, et al. Current surgical management of carotid body tumors. J Vasc Surg. 2016;64(6):1703-1710. doi:10.1016/j.jvs.2016.05.076
Fruhmann J, Geigl JB, Konstantiniuk P, Cohnert TU. Paraganglioma of the carotid body: treatment strategy and SDH-gene mutations. Eur J Vasc Endovasc Surg. 2013;45(5):431-436. doi:10.1016/j.ejvs.2013.01.018
King KS, Chen CC, Alexopoulos DK, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96(9):2779-2785. doi:10.1210/jc.2011-0333
Schiavi F, Savvoukidis T, Trabalzini F, et al. Paraganglioma syndrome: SDHB, SDHC, and SDHD mutations in head and neck paragangliomas. Ann N Y Acad Sci. 2006;1073:190-197. doi:10.1196/annals.1353.020
Bacca A, Sellari Franceschini S, Carrara D, et al. Sporadic or familial head neck paragangliomas enrolled in a single center: clinical presentation and genotype/phenotype correlations. Head Neck. 2013;35(1):23-27. doi:10.1002/hed.22910
Kunst HPM, Rutten MH, de Mönnink JP, et al. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res. 2011;17(2):247-254. doi:10.1158/1078-0432.CCR-10-0420
Zhu WD, Wang ZY, Chai YC, Wang XW, Chen DY, Wu H. Germline mutations and genotype-phenotype associations in head and neck paraganglioma patients with negative family history in China. Eur J Med Genet. 2015;58(9):433-438. doi:10.1016/j.ejmg.2015.05.008
Badenhop RF, Jansen JC, Fagan PA, et al. The prevalence of SDHB, SDHC, and SDHD mutations in patients with head and neck paraganglioma and association of mutations with clinical features. J Med Genet. 2004;41(7):e99. doi:10.1136/jmg.2003.011551
Boughdad S, O'Connor A, Cook GJ, et al. FDG PET-CT imaging in head and neck paragangliomas: a centre experience. Clin Endocrinol (Oxf). 2021;95(2):315-322. doi:10.1111/cen.14446
Hensen EF, Siemers MD, Jansen JC, et al. Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients. Clin Endocrinol (Oxf). 2011;75(5):650-655. doi:10.1111/j.1365-2265.2011.04097.x
Persu A, Lannoy N, Maiter D, et al. Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from Belgium: an update. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2012;44(5):349-353. doi:10.1055/s-0032-1311610
Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010;31(1):41-51. doi:10.1002/humu.21136
Udager AM, Magers MJ, Goerke DM, et al. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2018;71:47-54. doi:10.1016/j.humpath.2017.10.013
Smith JD, Ellsperman SE, Basura GJ, Else T. Re-evaluating the prevalence and factors characteristic of catecholamine secreting head and neck paragangliomas. Endocrinol Diabetes Metab. 2021;4(3):e00256. doi:10.1002/edm2.256
Menegolo M, Xodo A, Bozza R, et al. Improving outcomes in carotid body tumors treatment: the impact of a multidisciplinary team approach. Ann Vasc Surg. 2021;75:315-323. doi:10.1016/j.avsg.2021.01.074
Sridhara SK, Yener M, Hanna EY, Rich T, Jimenez C, Kupferman ME. Genetic testing in head and neck paraganglioma: who, what, and why? J Neurol Surg Part B Skull Base. 2013;74(4):236-240. doi:10.1055/s-0033-1342924
Kudryavtseva AV, Kalinin DV, Pavlov VS, et al. Mutation profiling in eight cases of vagal paragangliomas. BMC Med Genomics. 2020;13(8):115. doi:10.1186/s12920-020-00763-4
Chen H, Zhu W, Li X, Xue L, Wang Z, Wu H. Genetic and epigenetic patterns in patients with the head-and-neck paragangliomas associate with differential clinical characteristics. J Cancer Res Clin Oncol. 2017;143(6):953-960. doi:10.1007/s00432-017-2355-0
Bourdeau I, Grunenwald S, Burnichon N, et al. A SDHC founder mutation causes paragangliomas (PGLs) in the French Canadians: new insights on the SDHC-related PGL. J Clin Endocrinol Metab. 2016;101(12):4710-4718. doi:10.1210/jc.2016-1665
Cerqueira A, Seco T, Costa A, Tavares M, Cotter J. Pheochromocytoma and paraganglioma: a review of diagnosis, management and treatment of rare causes of hypertension. Cureus. 2020;12(5):e7969. doi:10.7759/cureus.7969
Nölting S, Ullrich M, Pietzsch J, et al. Current management of pheochromocytoma/paraganglioma: a guide for the practicing clinician in the era of precision medicine. Cancer. 2019;11(10):1505. doi:10.3390/cancers11101505
Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18(6):R253-R276. doi:10.1530/ERC-11-0170
Boedeker CC, Neumann HPH, Maier W, Bausch B, Schipper J, Ridder GJ. Malignant head and neck paragangliomas in SDHB mutation carriers. Otolaryngol Head Neck Surg. 2007;137(1):126-129. doi:10.1016/j.otohns.2007.01.015
Sandow L, Thawani R, Kim MS, Heinrich MC. Paraganglioma of the head and neck: a review. Endocr Pract. 2023;29(2):141-147. doi:10.1016/j.eprac.2022.10.002
Guha A, Musil Z, Vícha A, et al. A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas. Neoplasma. 2019;66(5):671-680. doi:10.4149/neo_2018_181208N933
Al-Harthy M, Al-Harthy S, Al-Otieschan A, Velagapudi S, Alzahrani AS. Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas. Endocr Pract. 2009;15(3):194-202. doi:10.4158/EP.15.3.194
Eisenhofer G, Timmers HJ, Lenders JWM, et al. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J Clin Endocrinol Metab. 2011;96(2):375-384. doi:10.1210/jc.2010-1588
Snezhkina AV, Fedorova MS, Pavlov VS, et al. Mutation frequency in main susceptibility genes among patients with head and neck paragangliomas. Front Genet. 2020;11:614908. doi:10.3389/fgene.2020.614908
Yonamine M, Wasano K, Aita Y, et al. Prevalence of germline variants in a large cohort of Japanese patients with pheochromocytoma and/or paraganglioma. Cancer. 2021;13(16):4014. doi:10.3390/cancers13164014
Smith JD, Harvey RN, Darr OA, et al. Head and neck paragangliomas: a two-decade institutional experience and algorithm for management. Laryngoscope Investig Otolaryngol. 2017;2(6):380-389. doi:10.1002/lio2.122
Gonzalez-Urquijo M, Viteri-Pérez VH, Becerril-Gaitan A, et al. Clinical characteristics and surgical outcomes of carotid body tumors: data from the carotid paraganglioma cooperative international registry (CAPACITY) group. World J Surg. 2022;46(10):2507-2514. doi:10.1007/s00268-022-06663-1
Yao L, Schiavi F, Cascon A, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA. 2010;304(23):2611-2619. doi:10.1001/jama.2010.1830
van Duinen N, Steenvoorden D, Kema IP, et al. Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metab. 2010;95(1):209-214. doi:10.1210/jc.2009-1632
Sen I, Young WF, Kasperbauer JL, et al. Tumor-specific prognosis of mutation-positive patients with head and neck paragangliomas. J Vasc Surg. 2020;71(5):1602-1612.e2. doi:10.1016/j.jvs.2019.08.232
Lloyd S, Obholzer R, Tysome J, BSBS Consensus Group. British skull base society clinical consensus document on management of head and neck paragangliomas. Otolaryngol Head Neck Surg. 2020;163(3):400-409. doi:10.1177/0194599820915490
McCrary HC, Babajanian E, Calquin M, et al. Characterization of malignant head and neck paragangliomas at a single institution across multiple decades. JAMA Otolaryngol Head Neck Surg. 2019;145(7):641-646. doi:10.1001/jamaoto.2019.1110
Makiese O, Chibbaro S, Marsella M, Tran Ba Huy P, George B. Jugular foramen paragangliomas: management, outcome and avoidance of complications in a series of 75 cases. Neurosurg Rev. 2012;35(2):185-194; discussion 194. doi:10.1007/s10143-011-0346-1
Borba LAB, Araújo JC, de Oliveira JG, et al. Surgical management of glomus jugulare tumors: a proposal for approach selection based on tumor relationships with the facial nerve. J Neurosurg. 2010;112(1):88-98. doi:10.3171/2008.10.JNS08612
Marretta AL, Ottaiano A, Iervolino D, et al. Response to peptide receptor radionuclide therapy in pheocromocytomas and paragangliomas: a systematic review and meta-analysis. J Clin Med. 2023;12(4):1494. doi:10.3390/jcm12041494
Zhou Y, Cui Y, Zhang D, Tong A. Efficacy and safety of tyrosine kinase inhibitors in patients with metastatic pheochromocytomas/paragangliomas. J Clin Endocrinol Metab. 2023;108(3):755-766. doi:10.1210/clinem/dgac657